The DLQI is the most frequently used instrument in studies of randomised controlled trials in dermatology. Instructions for use The Dermatology Life Quality Index questionnaire is …

While statins may reduce psoriasis severity, the meta-analysis did not show statistically significant improvements in PASI scores, except for topical application, and found no significant benefits …

Aug 15, 2024 · Between psoriasis (n = 723) and AD (n = 316) patients almost no differences were observed in happiness, SWL and NA, except for DLQI and small differences in PA, with AD …

May 27, 2022 · Clearance of psoriatic skin was observed in difficult-to-treat areas, with the percentage of patients achieving a PGA score ≤1 increasing between W28 and W52. …

This study demonstrates that DLQI and PASI remain low after 12 months, and, in fact, both gradually decline further with time. Patients on biologic agents for prolonged periods …

May 10, 2016 · To support the construct validity of the Itch NRS, large cross-sectional correlations with the Dermatology Life Quality Index (DLQI) Symptoms and Feelings domain (r ≥ 0·60 at …

Guselkumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or …

DLQI and PASI improved in the entire study population by 67.2% and 66.6%, respectively. Specifically, when analyzing patients who started Fumaderm® within 4 weeks before baseline …

The Dermatology Life Quality Index (DLQI) is the most frequently used health‐related quality of life (HRQoL) instrument for skin diseases. According to the DLQI instructions the responses “not …

This study demonstrates that DLQI and PASI remain low after 12 months, and, in fact, both gradually decline further with time. Patients on biologic agents for prolonged periods …